BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33222841)

  • 1. Functional imaging of adrenal cortex.
    Prado-Wohlwend S;
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):393-404. PubMed ID: 33222841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Para-chloro-2-[
    Silins I; Sundin A; Nordeman P; Jahan M; Estrada S; Monazzam A; Lubberink M; Aigbirhio F; Hellman P; Antoni G
    Int J Med Sci; 2021; 18(10):2187-2196. PubMed ID: 33859526
    [No Abstract]   [Full Text] [Related]  

  • 3. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG.
    Minn H; Salonen A; Friberg J; Roivainen A; Viljanen T; Långsjö J; Salmi J; Välimäki M; Någren K; Nuutila P
    J Nucl Med; 2004 Jun; 45(6):972-9. PubMed ID: 15181132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.
    Zettinig G; Mitterhauser M; Wadsak W; Becherer A; Pirich C; Vierhapper H; Niederle B; Dudczak R; Kletter K
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1224-30. PubMed ID: 15197504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing benign from malignant euadrenal masses.
    Gross MD; Shapiro B; Bouffard JA; Glazer GM; Francis IR; Wilton GP; Khafagi F; Sonda LP
    Ann Intern Med; 1988 Oct; 109(8):613-8. PubMed ID: 3421574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (18)F-FDG PET/CT of adrenal lesions.
    Dong A; Cui Y; Wang Y; Zuo C; Bai Y
    AJR Am J Roentgenol; 2014 Aug; 203(2):245-52. PubMed ID: 25055255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of molecular imaging in the personalized approach of patients with adrenal masses.
    Lorusso M; Rufini V; DE Crea C; Pennestrì F; Bellantone R; Raffaelli M
    Q J Nucl Med Mol Imaging; 2022 Jun; 66(2):104-115. PubMed ID: 35343669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses.
    Maurea S; Klain M; Mainolfi C; Ziviello M; Salvatore M
    J Nucl Med; 2001 Jun; 42(6):884-92. PubMed ID: 11390552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adrenal incidentaloma and nuclear medicine examination].
    Tenenbaum F
    J Radiol; 2009 Mar; 90(3 Pt 2):444-8. PubMed ID: 19421135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of 18F-FDG PET-CT and 131I-norcholesterol scintigraphy in the characterization of high-risk adrenal masses.
    Riaz S; Syed R; Aziz TA; Alnaim A; Chung TT; Wan S; Kurzawinski TR; Bomanji J
    Nucl Med Commun; 2020 Mar; 41(3):189-195. PubMed ID: 31895761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will
    Cuccurullo V; di Stasio GD; Evangelista L; Ciarmiello A; Mansi L
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):103-109. PubMed ID: 29422356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of [
    Bongarzone S; Basagni F; Sementa T; Singh N; Gakpetor C; Faugeras V; Bordoloi J; Gee AD
    Nucl Med Biol; 2019; 68-69():14-21. PubMed ID: 30578137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenal tuberculosis masquerading as disseminated malignancy: A pitfall of (18)F-FDG PET/CT Imaging.
    Gorla AK; Gupta K; Sood A; Biswal CK; Bhansali A; Mittal BR
    Rev Esp Med Nucl Imagen Mol; 2016; 35(4):257-9. PubMed ID: 26853485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A concomitant false-negative ¹⁸F-FDG PET imaging in an adrenocortical carcinoma and a high uptake in a corresponding liver metastasis.
    Ghander C; Tissier F; Tenenbaum F; Silvera S; Ragazzon B; Bertherat J; Bertagna X; Dousset B; Richard B; Legmann P; Groussin L
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1096-7. PubMed ID: 22319030
    [No Abstract]   [Full Text] [Related]  

  • 16. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques.
    Maurea S; Caracò C; Klain M; Mainolfi C; Salvatore M
    Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):188-97. PubMed ID: 15499292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidental focal colonic uptake in studies
    Servente L; Gigirey V; García Fontes M; Alonso O
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):15-19. PubMed ID: 28750749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentric study on ¹⁸F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes.
    Bertagna F; Evangelista L; Piccardo A; Bertoli M; Bosio G; Giubbini R; Orlando E; Treglia G
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):24-9. PubMed ID: 25312053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenal gland scintigraphy.
    Avram AM; Fig LM; Gross MD
    Semin Nucl Med; 2006 Jul; 36(3):212-27. PubMed ID: 16762612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metomidate-based imaging of adrenal masses.
    Hahner S; Sundin A
    Horm Cancer; 2011 Dec; 2(6):348-53. PubMed ID: 22124841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.